Moderna is pioneering messenger RNA Therapeutics™, an entirely new treatment modality that enables the body to produce therapeutic proteins in vivo. Moderna is using this approach to develop first-ever treatments for a wide range of diseases that cannot be addressed today using existing technologies, and to drastically reduce the time and expense associated with creating therapeutic proteins using recombinant technologies. The company has demonstrated proof-of-concept using messenger RNA Therapeutics for a variety of indications and is moving multiple programs into the clinic.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/06/12 | $40,000,000 |
Flagship Ventures | undisclosed | |
| 11/20/13 | $110,000,000 |
Flagship Ventures | undisclosed | |
| 01/06/15 | $450,000,000 |
Alexion Pharmaceuticals AstraZeneca Invus RA Capital Viking Global Investors Wellington Management Company | undisclosed | |
| 02/02/18 | $500,000,000 |
Abu Dhabi Investment Authority Alexandria Real Estate Equities ArrowMark Partners BB Biotech Ventures EDBI Fidelity Management & Research Company Julius Baer Pictet Viking Global Investors | undisclosed |
